+357 96 030922
info@marketpublishers.com

Global PD-1 and PD-L1 Monoclonal Antibodies Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GC80F671E5FCEN.html
Date: September 2026
Pages: 126
Price: US$ 4,480.00 (Single User License)
ID: GC80F671E5FCEN

Abstracts

The global PD-1 and PD-L1 Monoclonal Antibodies market size is expected to reach $ 2734 million by 2032, rising at a market growth of 7.5% CAGR during the forecast period (2026-2032).

PD-1 and PD-L1 monoclonal antibodies are a class of immune checkpoint inhibitors that activate the body's own T cells to kill tumor cells by blocking the signaling pathways of programmed cell death protein 1 (PD-1) or its ligand (PD-L1); they have become standard therapies for various solid tumors and hematological malignancies. In 2025, global sales volume reached approximately 3.8 million vials, with an average price of about $430 per vial based on standard treatment regimens—a figure reflecting global price disparities and the impact of biosimilars—while capacity utilization stood at approximately 83%. Upstream players include culture media manufacturers such as Thermo Fisher and Merck; Protein A affinity chromatography resin suppliers like Cytiva and Nanomicro; and single-use bioreactor provider Sartorius. Downstream entities include hospital pharmacies, oncology clinics, and distributors such as McKesson and Shanghai Pharmaceuticals, with gross margins generally maintained at a high level of 88% to 92%. The product cost structure comprises direct raw materials (e.g., serum-free media, chromatography media, and buffers) at approximately 22%; fixed asset depreciation and cleanroom facilities at 18%; R&D amortization and registration expenses at 35%; and sales, administrative, and channel costs at 15%. Regarding demand and business opportunities, downstream applications cover first-line and adjuvant indications such as non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, Hodgkin lymphoma, bladder cancer, esophageal cancer, and head and neck squamous cell carcinoma; key downstream clients include MD Anderson Cancer Center, Peking Union Medical College Hospital, Sinopharm Group, and Ali Health. Policy drivers include the inclusion of more PD-1 drugs in standard reimbursement lists

+357 96 030922
info@marketpublishers.com

following Chinese medical insurance negotiations and accelerated review pathways by global regulatory agencies. Technological innovation is evident in subcutaneous formulations, bispecific antibodies (e.g., PD-1/VEGF), and novel therapies combining PD-1 inhibitors with antibody-drug conjugates (ADCs). Finally, shifting consumer demands—with patients seeking longer survival, less frequent infusions, and reduced side effects like hair loss—are fueling interest in the development of long-acting injectables and oral formulations.

The PD-1 and PD-L1 monoclonal antibody market has transitioned from a phase of unchecked expansion to one of maturity and differentiation; while sales volumes continue to rise rapidly, prices are steadily declining due to biosimilars and national reimbursement negotiations, reflecting a strategy of trading price for volume. In the Chinese market, four domestic PD-1 products—from Junshi Biosciences, Innovent Biologics, BeiGene, and Hengrui Medicine—command over 70% of the market share, while imported drugs Keytruda (K-drug) and Opdivo (O-drug) maintain a high-end market stronghold by expanding into indications for early-stage cancer. The average unit price has dropped from tens of thousands of dollars in 2019 to the current national reimbursement price of approximately 3,000 RMB, and the global average price has fallen to $430 due to biosimilar penetration in India and Southeast Asia. A race to expand production capacity has left some companies with utilization rates of only 60%, whereas firms possessing high-expression cell lines and single-use bioreactor technologies maintain utilization rates exceeding 85% alongside lower costs. Future commercial opportunities lie in combination therapies and perioperative treatments; combinations involving PD-1 with chemotherapy, TIGIT, LAG-3, or ADCs are pushing new indications into the first-line setting, thereby extending treatment duration and expanding the patient base. Subcutaneous formulations, which reduce administration time to five minutes and significantly improve patient compliance, are emerging as a key tool for differentiation. On the policy front, the inclusion of early cancer screening in China’s "Healthy China 2030" agenda and the adoption of value-based (efficacy-linked) payment models in Europe and the US are driving higher penetration rates for PD-1 drugs. Furthermore, the expansion of indications into early-stage neoadjuvant and adjuvant settings has significantly lengthened treatment cycles for patients with resectable tumors, offsetting the impact of declining unit prices. Global PD-1 and PD-L1 usage is projected to exceed 1 billion patient-treatments by 2028; however, due to competition from biosimilars, sales revenue may see only modest growth, compelling innovative companies to rely on overseas expansion and combination patent strategies to sustain profitability.

+357 96 030922
info@marketpublishers.com

Report Scope

This report studies the global PD-1 and PD-L1 Monoclonal Antibodies demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for PD-1 and PD-L1 Monoclonal Antibodies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of PD-1 and PD-L1 Monoclonal Antibodies that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global PD-1 and PD-L1 Monoclonal Antibodies total market, 2021-2032, (USD Million)

Global PD-1 and PD-L1 Monoclonal Antibodies total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: PD-1 and PD-L1 Monoclonal Antibodies total market, key domestic companies, and share, (USD Million)

Global PD-1 and PD-L1 Monoclonal Antibodies revenue by player, revenue and market share 2021-2026, (USD Million)

Global PD-1 and PD-L1 Monoclonal Antibodies total market by Target, CAGR, 2021-2032, (USD Million)

Global PD-1 and PD-L1 Monoclonal Antibodies total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global PD-1 and PD-L1 Monoclonal Antibodies market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (CH), Merck KGaA (DE), AstraZeneca plc

+357 96 030922
info@marketpublishers.com

(GB), Regeneron Pharmaceuticals, Inc. (US), GSK plc (GB), Incyte Corporation (US), BIOCAD JSC (RU), BeOne Medicines Ltd. (CH), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world PD-1 and PD-L1 Monoclonal Antibodies market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Target, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global PD-1 and PD-L1 Monoclonal Antibodies Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

+357 96 030922
info@marketpublishers.com

Global PD-1 and PD-L1 Monoclonal Antibodies Market, Segmentation by Target:

PD-1 Monoclonal Antibody

PD-L1 Monoclonal Antibody

Global PD-1 and PD-L1 Monoclonal Antibodies Market, Segmentation by Antibody Origin:

Fully Human

Humanized

Global PD-1 and PD-L1 Monoclonal Antibodies Market, Segmentation by Dosing Interval:

Every 2 Weeks (Q2W)

Every 3 Weeks (Q3W)

Every 4 Weeks or Longer (?Q4W)

Global PD-1 and PD-L1 Monoclonal Antibodies Market, Segmentation by Application:

Lung Cancer Treatment

Melanoma Treatment

Bowel Cancer Treatment

Other

+357 96 030922
info@marketpublishers.com

Companies Profiled:

Merck & Co., Inc. (US)

Bristol Myers Squibb Company (US)

F. Hoffmann-La Roche Ltd (CH)

Merck KGaA (DE)

AstraZeneca plc (GB)

Regeneron Pharmaceuticals, Inc. (US)

GSK plc (GB)

Incyte Corporation (US)

BIOCAD JSC (RU)

BeOne Medicines Ltd. (CH)

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN)

Innovent Biologics, Inc. (CN)

Shanghai Junshi Biosciences Co., Ltd. (CN)

Shanghai Henlius Biotech, Inc. (CN)

Key Questions Answered

1. How big is the global PD-1 and PD-L1 Monoclonal Antibodies market?
2. What is the demand of the global PD-1 and PD-L1 Monoclonal Antibodies market?
3. What is the year over year growth of the global PD-1 and PD-L1 Monoclonal Antibodies market?
4. What is the total value of the global PD-1 and PD-L1 Monoclonal Antibodies market?

+357 96 030922
info@marketpublishers.com

5. Who are the Major Players in the global PD-1 and PD-L1 Monoclonal Antibodies market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 PD-1 and PD-L1 Monoclonal Antibodies Introduction
1.2 World PD-1 and PD-L1 Monoclonal Antibodies Market Size & Forecast (2021 & 2025 & 2032)
1.3 World PD-1 and PD-L1 Monoclonal Antibodies Total Market by Region (by Headquarter Location)
  1.3.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032)
  1.3.3 China Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032)
  1.3.4 Europe Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032)
  1.3.5 Japan Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032)
  1.3.6 South Korea Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032)
  1.3.7 ASEAN Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032)
  1.3.8 India Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 PD-1 and PD-L1 Monoclonal Antibodies Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032)
2.2 World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region
  2.2.1 World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2021-2026)
  2.2.2 World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Forecast by Region (2027-2032)
2.3 United States PD-1 and PD-L1 Monoclonal Antibodies Consumption Value

+357 96 030922
info@marketpublishers.com

(2021-2032)
2.4 China PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032)
2.5 Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032)
2.6 Japan PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032)
2.7 South Korea PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032)
2.8 ASEAN PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032)
2.9 India PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032)

3 WORLD PD-1 AND PD-L1 MONOCLONAL ANTIBODIES COMPANIES COMPETITIVE ANALYSIS

3.1 World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global PD-1 and PD-L1 Monoclonal Antibodies Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for PD-1 and PD-L1 Monoclonal Antibodies in 2025
  3.2.3 Global Concentration Ratios (CR8) for PD-1 and PD-L1 Monoclonal Antibodies in 2025
3.3 PD-1 and PD-L1 Monoclonal Antibodies Company Evaluation Quadrant
3.4 PD-1 and PD-L1 Monoclonal Antibodies Market: Overall Company Footprint Analysis
  3.4.1 PD-1 and PD-L1 Monoclonal Antibodies Market: Region Footprint
  3.4.2 PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Type Footprint
  3.4.3 PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Application Footprint
3.5 Competitive Environment
  3.5.1 Historical Structure of the Industry
  3.5.2 Barriers of Market Entry
  3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Revenue Comparison (by Headquarter Location)
  4.1.1 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Revenue

+357 96 030922
info@marketpublishers.com

Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Comparison
4.2.1 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based PD-1 and PD-L1 Monoclonal Antibodies Companies and Market Share, 2021-2026
4.3.1 United States Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (States, Country)
4.3.2 United States Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2021-2026)
4.4 China Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue and Market Share, 2021-2026
4.4.1 China Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2021-2026)
4.5 Rest of World Based PD-1 and PD-L1 Monoclonal Antibodies Companies and Market Share, 2021-2026
4.5.1 Rest of World Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2026)

5 MARKET ANALYSIS BY TARGET

5.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Overview by Target: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Target
5.2.1 PD-1 Monoclonal Antibody
5.2.2 PD-L1 Monoclonal Antibody
5.3 Market Segment by Target
5.3.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2021-2026)
5.3.2 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target

+357 96 030922
info@marketpublishers.com

(2027-2032)
5.3.3 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2027-2032)

6 MARKET ANALYSIS BY ANTIBODY ORIGIN

6.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Overview by Antibody Origin: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Antibody Origin
6.2.1 Fully Human
6.2.2 Humanized
6.3 Market Segment by Antibody Origin
6.3.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin (2021-2026)
6.3.2 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin (2027-2032)
6.3.3 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin (2027-2032)

7 MARKET ANALYSIS BY DOSING INTERVAL

7.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Overview by Dosing Interval: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Dosing Interval
7.2.1 Every 2 Weeks (Q2W)
7.2.2 Every 3 Weeks (Q3W)
7.2.3 Every 4 Weeks or Longer (?Q4W)
7.3 Market Segment by Dosing Interval
7.3.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval (2021-2026)
7.3.2 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval (2027-2032)
7.3.3 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Overview by Application: 2021 VS 2025 VS 2032

+357 96 030922
info@marketpublishers.com

8.2 Segment Introduction by Application
8.2.1 Lung Cancer Treatment
8.2.2 Melanoma Treatment
8.2.3 Bowel Cancer Treatment
8.2.4 Other
8.3 Market Segment by Application
8.3.1 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2021-2026)
8.3.2 World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2027-2032)
8.3.3 World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 Merck & Co., Inc. (US)
9.1.1 Merck & Co., Inc. (US) Details
9.1.2 Merck & Co., Inc. (US) Major Business
9.1.3 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.1.4 Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Merck & Co., Inc. (US) Recent Developments/Updates
9.1.6 Merck & Co., Inc. (US) Competitive Strengths & Weaknesses
9.2 Bristol Myers Squibb Company (US)
9.2.1 Bristol Myers Squibb Company (US) Details
9.2.2 Bristol Myers Squibb Company (US) Major Business
9.2.3 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.2.4 Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Bristol Myers Squibb Company (US) Recent Developments/Updates
9.2.6 Bristol Myers Squibb Company (US) Competitive Strengths & Weaknesses
9.3 F. Hoffmann-La Roche Ltd (CH)
9.3.1 F. Hoffmann-La Roche Ltd (CH) Details
9.3.2 F. Hoffmann-La Roche Ltd (CH) Major Business
9.3.3 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.3.4 F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies

+357 96 030922
info@marketpublishers.com

Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 F. Hoffmann-La Roche Ltd (CH) Recent Developments/Updates
9.3.6 F. Hoffmann-La Roche Ltd (CH) Competitive Strengths & Weaknesses
9.4 Merck KGaA (DE)
9.4.1 Merck KGaA (DE) Details
9.4.2 Merck KGaA (DE) Major Business
9.4.3 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.4.4 Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Merck KGaA (DE) Recent Developments/Updates
9.4.6 Merck KGaA (DE) Competitive Strengths & Weaknesses
9.5 AstraZeneca plc (GB)
9.5.1 AstraZeneca plc (GB) Details
9.5.2 AstraZeneca plc (GB) Major Business
9.5.3 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.5.4 AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 AstraZeneca plc (GB) Recent Developments/Updates
9.5.6 AstraZeneca plc (GB) Competitive Strengths & Weaknesses
9.6 Regeneron Pharmaceuticals, Inc. (US)
9.6.1 Regeneron Pharmaceuticals, Inc. (US) Details
9.6.2 Regeneron Pharmaceuticals, Inc. (US) Major Business
9.6.3 Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.6.4 Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Regeneron Pharmaceuticals, Inc. (US) Recent Developments/Updates
9.6.6 Regeneron Pharmaceuticals, Inc. (US) Competitive Strengths & Weaknesses
9.7 GSK plc (GB)
9.7.1 GSK plc (GB) Details
9.7.2 GSK plc (GB) Major Business
9.7.3 GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.7.4 GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 GSK plc (GB) Recent Developments/Updates
9.7.6 GSK plc (GB) Competitive Strengths & Weaknesses
9.8 Incyte Corporation (US)
9.8.1 Incyte Corporation (US) Details

+357 96 030922
info@marketpublishers.com

9.8.2 Incyte Corporation (US) Major Business
9.8.3 Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.8.4 Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Incyte Corporation (US) Recent Developments/Updates
9.8.6 Incyte Corporation (US) Competitive Strengths & Weaknesses
9.9 BIOCAD JSC (RU)
9.9.1 BIOCAD JSC (RU) Details
9.9.2 BIOCAD JSC (RU) Major Business
9.9.3 BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.9.4 BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 BIOCAD JSC (RU) Recent Developments/Updates
9.9.6 BIOCAD JSC (RU) Competitive Strengths & Weaknesses
9.10 BeOne Medicines Ltd. (CH)
9.10.1 BeOne Medicines Ltd. (CH) Details
9.10.2 BeOne Medicines Ltd. (CH) Major Business
9.10.3 BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.10.4 BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 BeOne Medicines Ltd. (CH) Recent Developments/Updates
9.10.6 BeOne Medicines Ltd. (CH) Competitive Strengths & Weaknesses
9.11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN)
9.11.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Details
9.11.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Major Business
9.11.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.11.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Recent Developments/Updates
9.11.6 Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Competitive Strengths & Weaknesses
9.12 Innovent Biologics, Inc. (CN)
9.12.1 Innovent Biologics, Inc. (CN) Details
9.12.2 Innovent Biologics, Inc. (CN) Major Business

+357 96 030922
info@marketpublishers.com

9.12.3 Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.12.4 Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Innovent Biologics, Inc. (CN) Recent Developments/Updates
9.12.6 Innovent Biologics, Inc. (CN) Competitive Strengths & Weaknesses
9.13 Shanghai Junshi Biosciences Co., Ltd. (CN)
9.13.1 Shanghai Junshi Biosciences Co., Ltd. (CN) Details
9.13.2 Shanghai Junshi Biosciences Co., Ltd. (CN) Major Business
9.13.3 Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.13.4 Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Shanghai Junshi Biosciences Co., Ltd. (CN) Recent Developments/Updates
9.13.6 Shanghai Junshi Biosciences Co., Ltd. (CN) Competitive Strengths & Weaknesses
9.14 Shanghai Henlius Biotech, Inc. (CN)
9.14.1 Shanghai Henlius Biotech, Inc. (CN) Details
9.14.2 Shanghai Henlius Biotech, Inc. (CN) Major Business
9.14.3 Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
9.14.4 Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Shanghai Henlius Biotech, Inc. (CN) Recent Developments/Updates
9.14.6 Shanghai Henlius Biotech, Inc. (CN) Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 PD-1 and PD-L1 Monoclonal Antibodies Industry Chain
10.2 PD-1 and PD-L1 Monoclonal Antibodies Upstream Analysis
10.3 PD-1 and PD-L1 Monoclonal Antibodies Midstream Analysis
10.4 PD-1 and PD-L1 Monoclonal Antibodies Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source

+357 96 030922
info@marketpublishers.com

12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key PD-1 and PD-L1 Monoclonal Antibodies Players in 2025
Table 12. World PD-1 and PD-L1 Monoclonal Antibodies Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global PD-1 and PD-L1 Monoclonal Antibodies Company Evaluation Quadrant
Table 14. Head Office of Key PD-1 and PD-L1 Monoclonal Antibodies Players
Table 15. PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Type Footprint
Table 16. PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Application Footprint
Table 17. PD-1 and PD-L1 Monoclonal Antibodies Mergers & Acquisitions Activity
Table 18. United States VS China PD-1 and PD-L1 Monoclonal Antibodies Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 20. United States Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 21. United States Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share (2021-2026)
Table 23. China Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (Province, Country)
Table 24. China Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share (2021-2026)
Table 26. Rest of World Based PD-1 and PD-L1 Monoclonal Antibodies Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share (2021-2026)
Table 29. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target, (USD Million), 2021 & 2025 & 2032
Table 30. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Value by Target (2021-2026) & (USD Million)
Table 31. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target (2027-2032) & (USD Million)
Table 32. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin, (USD Million), 2021 & 2025 & 2032
Table 33. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Value by Antibody Origin (2021-2026) & (USD Million)
Table 34. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin (2027-2032) & (USD Million)
Table 35. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval, (USD Million), 2021 & 2025 & 2032
Table 36. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Value by Dosing Interval (2021-2026) & (USD Million)
Table 37. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval (2027-2032) & (USD Million)
Table 38. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application

+357 96 030922
info@marketpublishers.com

(2021-2026) & (USD Million)
Table 40. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application (2027-2032) & (USD Million)
Table 41. Merck & Co., Inc. (US) Basic Information, Manufacturing Base and Competitors
Table 42. Merck & Co., Inc. (US) Major Business
Table 43. Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 44. Merck & Co., Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Merck & Co., Inc. (US) Recent Developments/Updates
Table 46. Merck & Co., Inc. (US) Competitive Strengths & Weaknesses
Table 47. Bristol Myers Squibb Company (US) Basic Information, Manufacturing Base and Competitors
Table 48. Bristol Myers Squibb Company (US) Major Business
Table 49. Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 50. Bristol Myers Squibb Company (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Bristol Myers Squibb Company (US) Recent Developments/Updates
Table 52. Bristol Myers Squibb Company (US) Competitive Strengths & Weaknesses
Table 53. F. Hoffmann-La Roche Ltd (CH) Basic Information, Manufacturing Base and Competitors
Table 54. F. Hoffmann-La Roche Ltd (CH) Major Business
Table 55. F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 56. F. Hoffmann-La Roche Ltd (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. F. Hoffmann-La Roche Ltd (CH) Recent Developments/Updates
Table 58. F. Hoffmann-La Roche Ltd (CH) Competitive Strengths & Weaknesses
Table 59. Merck KGaA (DE) Basic Information, Manufacturing Base and Competitors
Table 60. Merck KGaA (DE) Major Business
Table 61. Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 62. Merck KGaA (DE) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Merck KGaA (DE) Recent Developments/Updates
Table 64. Merck KGaA (DE) Competitive Strengths & Weaknesses
Table 65. AstraZeneca plc (GB) Basic Information, Manufacturing Base and

+357 96 030922
info@marketpublishers.com

Competitors
Table 66. AstraZeneca plc (GB) Major Business
Table 67. AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 68. AstraZeneca plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. AstraZeneca plc (GB) Recent Developments/Updates
Table 70. AstraZeneca plc (GB) Competitive Strengths & Weaknesses
Table 71. Regeneron Pharmaceuticals, Inc. (US) Basic Information, Manufacturing Base and Competitors
Table 72. Regeneron Pharmaceuticals, Inc. (US) Major Business
Table 73. Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 74. Regeneron Pharmaceuticals, Inc. (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Regeneron Pharmaceuticals, Inc. (US) Recent Developments/Updates
Table 76. Regeneron Pharmaceuticals, Inc. (US) Competitive Strengths & Weaknesses
Table 77. GSK plc (GB) Basic Information, Manufacturing Base and Competitors
Table 78. GSK plc (GB) Major Business
Table 79. GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 80. GSK plc (GB) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. GSK plc (GB) Recent Developments/Updates
Table 82. GSK plc (GB) Competitive Strengths & Weaknesses
Table 83. Incyte Corporation (US) Basic Information, Manufacturing Base and Competitors
Table 84. Incyte Corporation (US) Major Business
Table 85. Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 86. Incyte Corporation (US) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Incyte Corporation (US) Recent Developments/Updates
Table 88. Incyte Corporation (US) Competitive Strengths & Weaknesses
Table 89. BIOCAD JSC (RU) Basic Information, Manufacturing Base and Competitors
Table 90. BIOCAD JSC (RU) Major Business
Table 91. BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 92. BIOCAD JSC (RU) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 93. BIOCAD JSC (RU) Recent Developments/Updates
Table 94. BIOCAD JSC (RU) Competitive Strengths & Weaknesses
Table 95. BeOne Medicines Ltd. (CH) Basic Information, Manufacturing Base and Competitors
Table 96. BeOne Medicines Ltd. (CH) Major Business
Table 97. BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 98. BeOne Medicines Ltd. (CH) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. BeOne Medicines Ltd. (CH) Recent Developments/Updates
Table 100. BeOne Medicines Ltd. (CH) Competitive Strengths & Weaknesses
Table 101. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Basic Information, Manufacturing Base and Competitors
Table 102. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Major Business
Table 103. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 104. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Recent Developments/Updates
Table 106. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) Competitive Strengths & Weaknesses
Table 107. Innovent Biologics, Inc. (CN) Basic Information, Manufacturing Base and Competitors
Table 108. Innovent Biologics, Inc. (CN) Major Business
Table 109. Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 110. Innovent Biologics, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Innovent Biologics, Inc. (CN) Recent Developments/Updates
Table 112. Innovent Biologics, Inc. (CN) Competitive Strengths & Weaknesses
Table 113. Shanghai Junshi Biosciences Co., Ltd. (CN) Basic Information, Manufacturing Base and Competitors
Table 114. Shanghai Junshi Biosciences Co., Ltd. (CN) Major Business
Table 115. Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 116. Shanghai Junshi Biosciences Co., Ltd. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 117. Shanghai Junshi Biosciences Co., Ltd. (CN) Recent Developments/Updates
Table 118. Shanghai Junshi Biosciences Co., Ltd. (CN) Competitive Strengths & Weaknesses
Table 119. Shanghai Henlius Biotech, Inc. (CN) Basic Information, Manufacturing Base and Competitors
Table 120. Shanghai Henlius Biotech, Inc. (CN) Major Business
Table 121. Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Product and Services
Table 122. Shanghai Henlius Biotech, Inc. (CN) PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Shanghai Henlius Biotech, Inc. (CN) Recent Developments/Updates
Table 124. Shanghai Henlius Biotech, Inc. (CN) Competitive Strengths & Weaknesses
Table 125. Global Key Players of PD-1 and PD-L1 Monoclonal Antibodies Upstream (Raw Materials)
Table 126. Global PD-1 and PD-L1 Monoclonal Antibodies Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. PD-1 and PD-L1 Monoclonal Antibodies Picture
Figure 2. World PD-1 and PD-L1 Monoclonal Antibodies Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World PD-1 and PD-L1 Monoclonal Antibodies Total Revenue (2021-2032) & (USD Million)
Figure 4. World PD-1 and PD-L1 Monoclonal Antibodies Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company PD-1 and PD-L1 Monoclonal Antibodies Revenue (2021-2032) & (USD Million)
Figure 13. PD-1 and PD-L1 Monoclonal Antibodies Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)
Figure 16. World PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Region (2021-2032)
Figure 17. United States PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)
Figure 18. China PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)

+357 96 030922
info@marketpublishers.com

Figure 20. Japan PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)
Figure 23. India PD-1 and PD-L1 Monoclonal Antibodies Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of PD-1 and PD-L1 Monoclonal Antibodies by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for PD-1 and PD-L1 Monoclonal Antibodies Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for PD-1 and PD-L1 Monoclonal Antibodies Markets in 2025
Figure 27. United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Target, (USD Million), 2021 & 2025 & 2032
Figure 30. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target in 2025
Figure 31. PD-1 Monoclonal Antibody
Figure 32. PD-L1 Monoclonal Antibody
Figure 33. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Target (2021-2032)
Figure 34. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Antibody Origin, (USD Million), 2021 & 2025 & 2032
Figure 35. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin in 2025
Figure 36. Fully Human
Figure 37. Humanized
Figure 38. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Antibody Origin (2021-2032)
Figure 39. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Dosing Interval, (USD Million), 2021 & 2025 & 2032
Figure 40. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval in 2025
Figure 41. Every 2 Weeks (Q2W)

+357 96 030922
info@marketpublishers.com

Figure 42. Every 3 Weeks (Q3W)
Figure 43. Every 4 Weeks or Longer (?Q4W)
Figure 44. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Dosing Interval (2021-2032)
Figure 45. World PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 46. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application in 2025
Figure 47. Lung Cancer Treatment
Figure 48. Melanoma Treatment
Figure 49. Bowel Cancer Treatment
Figure 50. Other
Figure 51. World PD-1 and PD-L1 Monoclonal Antibodies Market Size Market Share by Application (2021-2032)
Figure 52. PD-1 and PD-L1 Monoclonal Antibodies Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global PD-1 and PD-L1 Monoclonal Antibodies Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GC80F671E5FCEN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GC80F671E5FCEN.html